22136-37-4

Usage

Explanation

The compound is composed of 9 carbon atoms, 8 hydrogen atoms, 4 nitrogen atoms, and 2 oxygen atoms.

Explanation

The compound consists of an imidazole ring (a five-membered heterocyclic ring with two nitrogen atoms) with a 4-methyl-2-nitrophenyl group attached to it.

Explanation

1-(4-Methyl-2-nitro-phenyl)-1H-imidazole is a derivative of the imidazole ring, which is a common structural motif in various biologically active compounds.

Explanation

Due to its structural features and potential biological activities, the compound may have applications in the development of pharmaceuticals and agrochemicals.

Explanation

As with any chemical compound, it is important to handle 1-(4-Methyl-2-nitro-phenyl)-1H-imidazole with care and follow appropriate safety measures to minimize the risk of hazardous properties.

Structure

1-(4-Methyl-2-nitro-phenyl)-1H-imidazole

Derivative

Imidazole

Potential applications

Pharmaceuticals and agrochemicals

Safety

Handle with care and follow proper safety protocols

Upstream product

• 288-32-4 1H-imidazole 
• 5326-39-6 4-iodo-3-nitrotoluene 
• 446-11-7 4-fluoro-3-nitrotoluene 

Relevant academic research and scientific papers

Nano copper(i) oxide/zinc oxide catalyzed N-arylation of nitrogen-containing heterocycles with aryl halides and arylboronic acids in air

The synergistic effect of zinc and copper in Cu2O/ZnO nanoflake as a heterogeneous catalyst for the N-arylation of heterocycles with aryl halides and arylboronic acids in the absence of additional ligand in air were demonstrated. The catalyst was characterized by powder X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), BET surface area measurement, and FT-IR spectroscopy. The Royal Society of Chemistry 2014.

MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV replication of formula (I) and the N-oxides, salts, or stereoisomers thereof, wherein each dashed line (represented by ------) represents an optional double bond; X is N, CH and where X bears a double bond it is C; R1 is -OR6, -NH-SO2R7; R2 is hydrogen, and where X is C or CH, R2 may also be C1-6alkyl; R3 is hydrogen, C1-6alkyl, C1-6alkoxyC1-6alkyl, or C3-7cycloalkyl; n is 3, 4, 5, or 6; R4 and R5 independently from one another are hydrogen, halo, hydroxy, nitro, cyano, carboxyl, C1-6alkyl, C1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkylcarbonyl, C1-6alkoxy- carbonyl, amino, azido, mercapto, C1-6alkylthio, polyhaloC1-6alkyl, aryl or Het; W is aryl or Het; R6 is hydrogen; aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; R7 is aryl; Het; C3-7cycloalkyl optionally substituted with C1-6alkyl; or C1-6alkyl optionally substituted with C3-7cycloalkyl, aryl or with Het; aryl is phenyl or naphthyl, each optionally substituted with 1-3 substituents; Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 - 4 heteroatoms each independently selected from N, O or S, and optionally substituted with 1 -3 substituents; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.